ECT Timing for Catatonia in Treatment-Resistant Bipolar Depression
A single patient, three days into catatonia within a treatment-resistant bipolar depressive episode. A benzodiazepine challenge is the standard first step — but her worsening medical fragility raises a real question of how much time that first step should be allowed to take.
B.W. is a 61-year-old retired high school teacher with bipolar I disorder who has been in a severe depressive episode for eight weeks, unresponsive to an adequate trial of lithium plus lurasidone and then a switch to quetiapine augmentation. Three days ago her presentation changed sharply: she stopped speaking almost entirely, sits in the same position for hours unless physically repositioned by staff, and on exam holds a raised arm in place after it is passively lifted rather than letting it fall — waxy flexibility, alongside mutism and marked psychomotor immobility. She has eaten almost nothing in three days and her family reports she has not gotten out of bed on her own since this began. This is catatonia, occurring within a severe bipolar depressive episode, and it is now a medical urgency as much as a psychiatric one — three days without meaningful oral intake in a 61-year-old raises real concern for dehydration and malnutrition, and immobility of this degree carries its own risk of blood clots.
The real positioning question is not whether to treat the catatonia — everyone agrees it needs urgent treatment — but which first-line approach to lead with under real time pressure. A lorazepam challenge is both diagnostic and often rapidly therapeutic for catatonia, lower-burden logistically, and can sometimes resolve the picture within hours to a day. ECT has the strongest and most reliable efficacy data for catatonia overall, especially for cases severe or medically precarious enough that waiting through a benzodiazepine trial carries its own real cost — and she is already three days into not eating, which shortens how much time genuinely exists to wait and see whether a first-line medication trial works before her medical status deteriorates further.
Racing a shrinking medical timeline
A lorazepam challenge is the standard first step for a reason — it's fast to start, low-burden, and often works well enough on its own that ECT never becomes necessary. I want to try it before committing to ECT consent and scheduling.
I agree with starting lorazepam, but I don't want ECT treated as a fallback we only start thinking about after it fails — she is three days into not eating and immobile enough to carry real medical risk. If we wait to begin ECT consent and scheduling until after a lorazepam trial has had time to fail, we've lost a day or two we may not have.
This isn't choosing ECT over lorazepam. It's refusing to run them as strictly sequential steps when her medical fragility argues for parallel preparation.
From the medical side, I agree the clock matters here — I want IV fluids and close vital sign and intake monitoring started now regardless of which psychiatric treatment path moves fastest, and a low threshold to escalate if her intake doesn't improve within the first 24 hours.
Lorazepam 2mg IV given with a plan to reassess response within a few hours and repeat if partial. ECT consent process and scheduling started the same day, running in parallel rather than waiting on the outcome of the lorazepam trial. IV fluids and close vital sign and oral intake monitoring started immediately.
The team was explicit that this is not a competition between two treatments but a timeline problem: if lorazepam resolves the catatonia within the next day, ECT scheduling would be paused rather than completed; if it does not, ECT is already in motion rather than only beginning to be arranged after a failed trial has cost additional days she may not have to spare.